Digitalis has launched a $100m fund focused on seed- and early-stage companies seeking to address the most challenging problems in human health.
Founded in 2016 by Geoffrey W. Smith, managing partner, Digitalis invests in solutions at the intersection of math, physics, computing, chemistry and biology.
Digitalis targets early-stage companies seeking to achieve proof-of-concept, complete product development or demonstrate product-market fit. The firm is also actively looking to co-found new companies that demonstrate promise in solving major health challenges.
To date, the firm has invested in three companies:
– CareDox, which provides a unified digital health platform that covers over 1.8 million students in the public school system;
Girihlet, which uses T-cell sequencing technology to enable longitudinal monitoring of human health through the immune system; and
Second Genome, which leverages a computational microbiome platform for broad applications in humans, plants and animals.
The firm, which has offices in New York, San Francisco and Los Angeles, is also led by partners Steve Allen, Drew Taylor, technocal partner Dac Nguyen and principal Amit Bansal.
Scientific advisors include Carlos Bustamante, Brian Naughton and Glenn Nedwin.